Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002

Keizo Yamaguchi; Yoshikazu Ismi; Morihiro Iwata; Naoki Watanabe; Nobuyuki Uehara; Minoru Yasujima; Takeshi Kasai; Akira Suwabe; Ritsuko Obata; Mitsuo Kaku; Keiji Kanemitsu; Hiroshi Yoshida; Toshio Satoh; Masami Murakami; Ayako Takahashi; Kouichi Itoh; Yasuhiro Shibuya; Harushegi Kanno; Setsuko Kubo; Shigefumi Maesaki; Giichi Hashikita; Jun Igari; Toyoko Oguri; Jun Okada; Yoko Tazawa; Hideki Nakashima; Hiromu Takemura; Toshinobu Horii; Hisashi Baba; Shiomi Ishigo; Naohisa Fujita; Tosiiiaki Komori; Satoshi Ichiyama; Shigetaka Maeda; Kiyoharu Yamanaka; Yoko Murata; Masanori Aihara; Shohiro Kinoshita; Tomohiko Taminato; Kiyoshi Negayama; Mitsuharu Murase; Hitoshi Miyamoto; Nobuuchika Kusano; Eiichirou Mihara; Masayum Kambe; Hideyuki Itaha; Junko Ono; Hisae Yoshimura; Yoichi Hirakata; Junichi Matsuda; Tetsunori Saikawa; Kazufumi Hiramatsu

Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002

Keizo Yamaguchi, Yoshikazu Ismi, Morihiro Iwata, Naoki Watanabe, Nobuyuki Uehara, Minoru Yasujima, Takeshi Kasai, Akira Suwabe, Ritsuko Obata, Mitsuo Kaku, Keiji Kanemitsu, Hiroshi Yoshida, Toshio Satoh, Masami Murakami, Ayako Takahashi, Kouichi Itoh, Yasuhiro Shibuya, Harushegi Kanno, Setsuko Kubo, Shigefumi MaesakiGiichi Hashikita, Jun Igari, Toyoko Oguri, Jun Okada, Yoko Tazawa, Hideki Nakashima, Hiromu Takemura, Toshinobu Horii, Hisashi Baba, Shiomi Ishigo, Naohisa Fujita, Tosiiiaki Komori, Satoshi Ichiyama, Shigetaka Maeda, Kiyoharu Yamanaka, Yoko Murata, Masanori Aihara, Shohiro Kinoshita, Tomohiko Taminato, Kiyoshi Negayama, Mitsuharu Murase, Hitoshi Miyamoto, Nobuuchika Kusano, Eiichirou Mihara, Masayum Kambe, Hideyuki Itaha, Junko Ono, Hisae Yoshimura, Yoichi Hirakata, Junichi Matsuda, Tetsunori Saikawa, Kazufumi Hiramatsu

University Hospital

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

The antibacterial activity of meropenem (MEPM) and odler paremeral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC ₉₀ of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 7 years after available for commercial use.

Original language	English
Pages (from-to)	70-104
Number of pages	35
Journal	Japanese Journal of Antibiotics
Volume	57
Issue number	1
Publication status	Published - Feb 2004

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Yamaguchi, K., Ismi, Y., Iwata, M., Watanabe, N., Uehara, N., Yasujima, M., Kasai, T., Suwabe, A., Obata, R., Kaku, M., Kanemitsu, K., Yoshida, H., Satoh, T., Murakami, M., Takahashi, A., Itoh, K., Shibuya, Y., Kanno, H., Kubo, S., ... Hiramatsu, K. (2004). Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002. Japanese Journal of Antibiotics, 57(1), 70-104.

Yamaguchi, K, Ismi, Y, Iwata, M, Watanabe, N, Uehara, N, Yasujima, M, Kasai, T, Suwabe, A, Obata, R, Kaku, M, Kanemitsu, K, Yoshida, H, Satoh, T, Murakami, M, Takahashi, A, Itoh, K, Shibuya, Y, Kanno, H, Kubo, S, Maesaki, S, Hashikita, G, Igari, J, Oguri, T, Okada, J, Tazawa, Y, Nakashima, H, Takemura, H, Horii, T, Baba, H, Ishigo, S, Fujita, N, Komori, T, Ichiyama, S, Maeda, S, Yamanaka, K, Murata, Y, Aihara, M, Kinoshita, S, Taminato, T, Negayama, K, Murase, M, Miyamoto, H, Kusano, N, Mihara, E, Kambe, M, Itaha, H, Ono, J, Yoshimura, H, Hirakata, Y, Matsuda, J, Saikawa, T & Hiramatsu, K 2004, 'Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002', Japanese Journal of Antibiotics, vol. 57, no. 1, pp. 70-104.

@article{a007014e846a4d00886cc415ad9d341c,

title = "Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002",

abstract = "The antibacterial activity of meropenem (MEPM) and odler paremeral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC 90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 7 years after available for commercial use.",

author = "Keizo Yamaguchi and Yoshikazu Ismi and Morihiro Iwata and Naoki Watanabe and Nobuyuki Uehara and Minoru Yasujima and Takeshi Kasai and Akira Suwabe and Ritsuko Obata and Mitsuo Kaku and Keiji Kanemitsu and Hiroshi Yoshida and Toshio Satoh and Masami Murakami and Ayako Takahashi and Kouichi Itoh and Yasuhiro Shibuya and Harushegi Kanno and Setsuko Kubo and Shigefumi Maesaki and Giichi Hashikita and Jun Igari and Toyoko Oguri and Jun Okada and Yoko Tazawa and Hideki Nakashima and Hiromu Takemura and Toshinobu Horii and Hisashi Baba and Shiomi Ishigo and Naohisa Fujita and Tosiiiaki Komori and Satoshi Ichiyama and Shigetaka Maeda and Kiyoharu Yamanaka and Yoko Murata and Masanori Aihara and Shohiro Kinoshita and Tomohiko Taminato and Kiyoshi Negayama and Mitsuharu Murase and Hitoshi Miyamoto and Nobuuchika Kusano and Eiichirou Mihara and Masayum Kambe and Hideyuki Itaha and Junko Ono and Hisae Yoshimura and Yoichi Hirakata and Junichi Matsuda and Tetsunori Saikawa and Kazufumi Hiramatsu",

year = "2004",

month = feb,

language = "English",

volume = "57",

pages = "70--104",

journal = "The Journal of antibiotics. Ser. B",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "1",

}

TY - JOUR

T1 - Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002

AU - Yamaguchi, Keizo

AU - Ismi, Yoshikazu

AU - Iwata, Morihiro

AU - Watanabe, Naoki

AU - Uehara, Nobuyuki

AU - Yasujima, Minoru

AU - Kasai, Takeshi

AU - Suwabe, Akira

AU - Obata, Ritsuko

AU - Kaku, Mitsuo

AU - Kanemitsu, Keiji

AU - Yoshida, Hiroshi

AU - Satoh, Toshio

AU - Murakami, Masami

AU - Takahashi, Ayako

AU - Itoh, Kouichi

AU - Shibuya, Yasuhiro

AU - Kanno, Harushegi

AU - Kubo, Setsuko

AU - Maesaki, Shigefumi

AU - Hashikita, Giichi

AU - Igari, Jun

AU - Oguri, Toyoko

AU - Okada, Jun

AU - Tazawa, Yoko

AU - Nakashima, Hideki

AU - Takemura, Hiromu

AU - Horii, Toshinobu

AU - Baba, Hisashi

AU - Ishigo, Shiomi

AU - Fujita, Naohisa

AU - Komori, Tosiiiaki

AU - Ichiyama, Satoshi

AU - Maeda, Shigetaka

AU - Yamanaka, Kiyoharu

AU - Murata, Yoko

AU - Aihara, Masanori

AU - Kinoshita, Shohiro

AU - Taminato, Tomohiko

AU - Negayama, Kiyoshi

AU - Murase, Mitsuharu

AU - Miyamoto, Hitoshi

AU - Kusano, Nobuuchika

AU - Mihara, Eiichirou

AU - Kambe, Masayum

AU - Itaha, Hideyuki

AU - Ono, Junko

AU - Yoshimura, Hisae

AU - Hirakata, Yoichi

AU - Matsuda, Junichi

AU - Saikawa, Tetsunori

AU - Hiramatsu, Kazufumi

PY - 2004/2

Y1 - 2004/2

N2 - The antibacterial activity of meropenem (MEPM) and odler paremeral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC 90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 7 years after available for commercial use.

AB - The antibacterial activity of meropenem (MEPM) and odler paremeral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC 90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 7 years after available for commercial use.

UR - http://www.scopus.com/inward/record.url?scp=12144286756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144286756&partnerID=8YFLogxK

M3 - Review article

C2 - 15116574

AN - SCOPUS:12144286756

VL - 57

SP - 70

EP - 104

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 1

ER -

Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this